---
title: "MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290055475.md"
description: "A biotechnology company called MetaVia Inc., which focuses on transforming cardiometabolic diseases, revealed that its President and CEO, Hyung Heon Kim, is set to take part in a fireside chat. The company made this announcement today in Cambridge, Mass., dated June 17, 2026. MetaVia Inc. is listed on Nasdaq with the ticker symbol MTVA."
datetime: "2026-06-17T12:33:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290055475.md)
  - [en](https://longbridge.com/en/news/290055475.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290055475.md)
generator: "portal-rs"
---

# MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

A biotechnology company called MetaVia Inc., which focuses on transforming cardiometabolic diseases, revealed that its President and CEO, Hyung Heon Kim, is set to take part in a fireside chat. The company made this announcement today in Cambridge, Mass., dated June 17, 2026. MetaVia Inc. is listed on Nasdaq with the ticker symbol MTVA.

### Related Stocks

- [MTVA.US](https://longbridge.com/en/quote/MTVA.US.md)

## Related News & Research

- [Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy](https://longbridge.com/en/news/296478943.md)
- [Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301](https://longbridge.com/en/news/296321067.md)
- [Biomarin To Acquire Alesta Therapeutics To Gain Ale1, A Potential First Oral Therapy For Hypophosphatasia](https://longbridge.com/en/news/296228796.md)
- [MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies | MXCT Stock News](https://longbridge.com/en/news/296353997.md)
- [CPS Technologies leases 80,000-sq-ft Attleboro, Massachusetts facility to expand operations](https://longbridge.com/en/news/296531870.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**